Skip to main content

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

Written by Customer Service on . Posted in Public Companies.

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The grant was approved by a majority of the independent directors of the Company on January 6, 2023, as an inducement material to Mr. Tan’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant to Mr. Tan consisted of an option to purchase up to 90,000 shares of common stock and a restricted stock unit award with respect to 45,000 shares of common stock. The option has a ten-year term and an exercise price of $6.00 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on January 9, 2023. The option award vests over four years, with 25% of the original number of shares underlying the option vesting on the one-year anniversary of the date of grant and 1/48th of the original number of shares vesting monthly thereafter, and the restricted stock unit award vests in four equal installments on each one-year anniversary of Mr. Tan’s employment start date until the fourth anniversary of Mr. Tan’s start date, subject to Mr. Tan’s continued service with the Company through the applicable vesting dates.

About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.